are labor-intensive, and require specialized expertise, TC and the CCCA are not currently used as routine diagnostic methods in the United States. Commercially available assays include enzyme immunoassays (EIAs) for toxins A and B, EIAs for glutamate dehydrogenase, and nucleic acid amplification tests (NAATs). NAAT sensitivity approaches that of TC, and this methodology is now the most commonly used in the United States to detect C. difficile in stool (7) .
There is increasing recognition that NAATs detect asymptomatically colonized patients and have poor specificity for CDI and that careful patient selection for C. difficile testing would decrease false-positive tests for CDI (2, 3, 8) . However, data on the impact of clinical characteristics and pretest probability of CDI on CDI diagnosis are scarce. Thus, the objective of this study was to evaluate the clinical characteristics and outcomes of hospitalized patients tested for C. difficile and determine the correlation between pretest probability for CDI and assay results.
RESULTS
Demographics. Among the 111 patients enrolled in the study, stool samples from four (3.6%) were positive by toxin EIA (EIA ϩ ) and samples from nine (8.1%) were TC positive (TC ϩ ). In this sample, there were 2 EIA ϩ /TC ϩ , 7 EIA Ϫ /TC ϩ , 2 EIA ϩ /TC Ϫ , and 100 EIA Ϫ /TC Ϫ patients. Patient demographics and clinical characteristics are shown in Table  1 . Potential reasons for diarrhea, other than CDI, were identified and included 22 (20%) patients with recent chemotherapy, 18 (16%) that received a laxative within the 24 h prior to the test request, and 15 (14%) that were receiving tube feeds. The presence of clinically significant diarrhea (CSD) could not be assessed in 31 (28%) patients. Among those for which it was possible to determine the severity of diarrhea (n ϭ 80), 61 (76%) patients experienced CSD. Among those with CSD (n ϭ 61), potential non-CDI reasons for diarrhea included 14 (23%) patients undergoing chemotherapy and 9 (15%) who had received a laxative in the previous 24 h (Table 2 ). There were significant differences in recent chemotherapy or tube feeds by CSD status (Table 2) .
Pretest probability for CDI. Overall, 72 (65%) patients were assessed as having low pretest probability for CDI, 34 (31%) as having a medium probability, and 5 (5%) as having a high probability (Fig. 1 ). There were significant differences (P Ͻ 0.05) among patients by pretest classification for the following characteristics: empiric CDI treatment, abdominal tenderness, leukocytosis, and toxin EIA results (Table 3) . Among the four patients (3.6%) with positive toxin EIA results, three had been rated as having a medium probability for CDI and one had been rated as having a high probability. The characteristics of these patients are given in Table 4 . The median 90-day survival was 90 days for the low and medium groups and 76 days for the high pretest probability of CDI (log rank, P Ͻ 0.01).
Of the five patients with a high pretest probability of CDI, two (40%) of these patients had CSD. The presence of CSD could not be determined for the other three patients due to a lack of information from the patient or clinical team about the patient's stool type or stool frequency. Further examination of these five high pretest probability patients indicate that they all had high medical acuity and/or underlying immunosuppression, none were on laxatives, and three were on empiric treatment for CDI prior to testing. Two patients were critically ill in the medical intensive care unit, and four had an active hematopoietic malignancy.
One patient with a high pretest probability of CDI had a positive toxin EIA and a negative TC result. This patient had a history of a hematopoietic malignancy with recent chemotherapy and treatment with broad-spectrum antibiotics for health careassociated pneumonia a month prior to the positive EIA. At the time of the positive toxin EIA, the patient was toxic appearing, neutropenic, had diarrhea documented by the clinical provider, and received empiric CDI treatment with metronidazole. A computed tomography (CT) scan of the abdomen demonstrated diffuse bowel wall edema of the colon. The patient was ultimately diagnosed with a perforated bowel due to diverticulitis and associated Escherichia coli bacteremia. Toxigenic culture. C. difficile was recovered in culture from the stool of 14 patients, of which 9 were toxigenic. Four isolates were positive for tcdA, tcdB, and cdtA and cdtB. The remaining five had only tcdA and tcdB detected. The following five different strain types were identified: PCR ribotype 027 (n ϭ 3), 014/020 (n ϭ 3), one each of ribotypes 
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015/046 and 106/174, and a strain type previously characterized at Washington University (WU) but without a match in the European Centre for Disease Prevention and Control (ECDC)-Cardiff reference strains named WU8 (4). Characteristics of these nine patients are given in Table 5 and are stratified by pretest probability of CDI. Two culture-positive patients had positive toxin EIA results and were treated for CDI. None of the seven patients with a positive TC but negative EIA developed CDI within 30 days after the index EIA or died within 90 days after the index toxin EIA date. Only one TC-positive/EIA-negative patient had been started on empiric treatment with oral metronidazole prior to culture. One patient who had a positive index EIA and positive index TC (ribotype 027) died within 90 days of the toxin EIA.
There was no significant difference in survival at 90 days post-EIA between patients who were culture positive and EIA negative (n ϭ 7) and patients who were culture negative and EIA negative (n ϭ 100) (0% EIA Ϫ /TC ϩ died versus 11% EIA Ϫ /TC Ϫ ; log rank, P ϭ 0.37). Repeat testing. Eight patients had a repeat test ordered within 96 h of the index test. Five of these patients were assigned a low pretest probability of CDI, two had a medium probability, and one had a high probability. Two of these patients had an index test which was EIA negative and TC positive (both were positive for tcdA and tcdB; ribotypes 106/174 and 014/020). The patient with ribotype 106/174 had been assigned a high pretest probability of CDI, had not received empiric CDI treatment, and had a negative repeat EIA but a positive TC. The patient with ribotype 014/020 had been assigned a medium pretest probability of CDI, had not received empiric CDI treatment, and had a negative repeat EIA and a negative TC. None of the eight patients with repeat tests within 96 h were treated for CDI or were diagnosed with CDI within 30 days, including the patients with cultures that were positive for toxigenic C. difficile. One of the eight patients died within 90 days for reasons unrelated to CDI (oncology patient with low pretest probability of CDI). Only 1 out of the 111 patients had a positive C. difficile EIA within the 30 days after the index EIA and negative TC. This patient had a history of acute myeloid leukemia and, at the time of the negative index EIA and TC tests, was classified as having a low probability of CDI. After the index test, the patient underwent hematopoietic stem cell transplantation (HSCT) and subsequently developed neutropenic fever and diarrhea. Seven days after the index test, the patient had a positive EIA and TC (positive for tcdA, tcdB, and cdtA and cdtB; PCR ribotype 126).
DISCUSSION
This study adds to the growing body of evidence that laboratory testing alone is insufficient to confirm a diagnosis of CDI. Existing data suggest that many patients tested for C. difficile do not have a clinical syndrome compatible with CDI and/or have alternative causes of diarrhea. The results of this study emphasize the tenet that a patient's clinical presentation should be taken into account prior to ordering, and when interpreting, laboratory testing for C. difficile.
Of the patients for whom we were able to determine diarrhea severity, only 76% had CSD. A substantial portion of patients had other medical conditions or were on laxatives that may have caused diarrhea at the time of the C. difficile test. Similarly, in a study designed to validate a PCR assay for C. difficile, Peterson et al. found that 39% of submitted stool samples came from patients who had fewer than three diarrheal stools per day (9). Su et al. performed a clinical review during an evaluation of a NAAT-based assay and found that 21% of patients no longer had diarrhea (Ն3 loose stools within 24 h) at the time of sample collection (10). In our study, 16% were receiving a laxative within 24 h prior to C. difficile testing, including a patient receiving polyethylene glycol in preparation for a colonoscopy. The use of laxatives prior to C. difficile testing was previously documented in studies by Buckel et al. and Dubberke et al., which noted that up to 19% to 44% of patients tested for C. difficile had documented laxative use in the 48 h prior to stool collection (5, 11) .
We were unable to assess for the presence of CSD in 28% of patients due to the absence of data from the patient or clinical team on the patient's stool consistency or frequency. Reasons for the lack of data included patient factors, such as the inability to communicate due to critical illness or dementia, as well as health care worker factors, such as a lack of documentation of clinical symptoms and stool frequency. The inability of patients to communicate their symptoms is a limitation that clinicians face on a daily basis, as many patients and caregivers are unable to consistently communicate due to their medical comorbidities (for example, debilitating stroke or critical illness). Improved methods for the documentation of stool consistency and frequency in the medical health record may help clinicians accurately determine which patients should be tested for C. difficile.
In this sample, 65% of patients had a low pretest probability for CDI. Notably, none of these patients had a positive C. difficile EIA, and none of the four low-probability patients colonized with toxigenic C. difficile developed CDI-attributable complications. Alternate causes of diarrhea were found in many of these patients, and often their clinical presentations were not concerning for CDI after thoughtful review. This suggests that C. difficile testing may not be indicated in patients with a low pretest probability for CDI.
There were some notable cases in this cohort that warrant further discussion. One patient with a high pretest probability for CDI had a positive EIA but a negative TC result. This patient had been on empiric CDI treatment with metronidazole prior to testing and was ultimately diagnosed with a perforated bowel due to diverticulitis and associated Escherichia coli bacteremia. A potential explanation for the negative culture is that the metronidazole inhibited growth in culture. Alternatively, the EIA was falsely positive, and all symptoms were due to diverticulitis and bacteremia. Another patient had a positive EIA and TC 7 days after a negative index EIA and TC. This patient had a history of acute myeloid leukemia, and at the time of the index test, she was classified as having a low probability of CDI. Within that 7-day time period, the patient underwent HSCT and subsequently developed neutropenic fever and diarrhea. The median incubation period from C. difficile acquisition to CDI is Ͻ7 days (12) . Given the continued hospital exposure and immunocompromised state, it is likely that this patient acquired C. difficile and developed CDI after the negative index test.
None of the seven patients with a negative index EIA but positive TC developed CDI within 30 days after the index EIA or died within 90 days after the index test. Of the eight patients who had a repeat test ordered within 96 h of a negative index test, two patients had an index test which was EIA negative and TC positive. Neither had received empiric CDI treatment, both had negative repeat EIAs, one had a positive repeat TC, and neither was diagnosed with CDI or died within 30 days of the index EIA. Although patients may have clinical syndromes concerning for CDI, they may be colonized with C. difficile and not have actual CDI. These findings are consistent with prior literature; Polage et al. demonstrated that C. difficile-attributable complications are rare among patients with a negative C. difficile toxin EIA (13) . In another study, Polage et al. demonstrated that presentation and CDI-related complications were no different in patients that had negative toxin EIA and PCR tests than they were in patients with negative toxin EIA and positive PCR tests (14) .
There are several limitations to this study. First, it was relatively small and it was conducted over a short time frame at a single institution; a larger study with a longer assessment period would allow for more robust statistical analyses of CDI-related outcomes and mortality. Second, the pretest CDI probabilities were assigned by a single physician. As we have emphasized, CDI is a diagnosis that relies heavily on clinical judgment, and our results may have been biased by the assessments of one physician's judgment. Outcomes based on CDI probability suggest that this is not the case; median survival was shortest in the high pretest probability group (90, 90, and 76 days in the low, medium, and high probability groups, respectively). In the current investigation, we did not perform a molecular test for C. difficile; however, previous studies have shown that when PCR is used to detect C. difficile in hospitalized patients with diarrhea, the sensitivity approaches that of TC (7, 15) .
This study provides additional emphasis on the importance of patients' clinical symptoms for the interpretation of C. difficile diagnostic assays. Assignment of a pretest probability for CDI at the time of testing is a novel approach for assessing the impact of the overall clinical picture on the interpretation of C. difficile assay results. As we assessed patients in real-time and did not exclude patients who could not communicate their stool characteristics or frequency, this study is generalizable to the circumstances that clinicians encounter on a daily basis. Data regarding the patient's symptoms and clinical exam were collected prospectively; we were not limited by retrospective medical record data. Given the prospective data collection, we were able to collect a more complete record of a patient's stool characteristics, as often diarrhea is incompletely captured in a medical chart. Further prospective studies of this nature would be of value.
Clinicians and health care facilities continue to search for a C. difficile test that is simultaneously rapid, sensitive, and specific for CDI. Certainly, more research is needed on diagnostic methods for CDI, especially given the important consideration of asymptomatic colonization. However, perhaps the difficulties encountered in CDI diagnosis are less a failure of diagnostic technology than an overreliance on diagnostic tests and an underreliance on clinical assessments. Moving forward, methods and guidelines to diagnose CDI that couple laboratory-based C. difficile detection with clinical assessments need to be developed.
